Group items tagged

Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.

Read on to know about Cluster Headaches. Cluster headache is characterized by recurrent attacks of unilateral pain, which are very severe and is associated with symptoms of activation of the cranial autonomic pathways like lacrimation, conjunctival stuffiness, nasal congestion, rhinorrhea, and periorbitaloedema. The attacks are one sided, last for about 15 minutes to three hours, and have a characteristic set of cranial autonomic features as described above and are associated with agitation. Most patients describe restlessness and agitation during an attackand bang their heads and wish to rest in cold environment isolated from people. How Long Does The Attack Last? What is the frequency?

The 'Life and Health Sciences Launchpad' has been introduced to focus on the precision medicine sector. It would help businesses and researchers to level up their impact on economic growth within the region. The launchpad has been funded by Innovate UK, part of UK Research and Innovation (UKRI). Kerry Curran, Director of GB & EU Trade in the Department for the Economy hailed the decision to support NI's "trailblazing" sector. She said: "Life and Health Science, including our highly innovative precision medicine cluster, is an area the Department is also prioritising through its 10X Economy Vision, and this Launchpad represents a further endorsement of the world-leading growth potential of precision medicine, and indeed life and health science, in Northern Ireland.

Nevus is usually called moles in simple terms. When the skin cells known as melanocytes that are responsible for producing melanin in our skin grow in clusters rather than individually, moles start to appear.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

Pharmanovia, the lifecycle management company has signed a licence and supply agreement with Aquestive Therapeutics for its patented diazepam buccal film formulation across the EU, UK, Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA)- up to 48 markets in total. Aquestive Therapeutics has been granted tentative approval by the US Food and Drug Administration (FDA), for its diazepam buccal film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. Pharmanovia will be responsible for seeking appropriate regulatory approval across EU and MENA. Pharmanovia CEO, James Burt commented: "Pharmanovia and Aquestive are aligned in our mission to find new and innovative ways to enhance and revitalise iconic medicines. We have extensive experience with diazepam through the Valium brand and, together with Aquestive's unique PharmFilm technology, we're intending to bring a novel alternative diazepam delivery option to caregivers and patients at a time of critical need."

The UK Health Security Agency (UKHSA) has raised alarm over rising cases of extensively antibiotic-resistant Shigella infections, mainly in gay, bisexual, and other men who have physical relationship with men (GBMSM). There has been a 53 per cent increase in cases since the beginning of 2023, mostly driven by a cluster of antibiotic resistant strain called Shigella sonnei, with 97 cases reported this year until November, compared to just four cases last year. According to UKHSA, Shigella sonnei infections are difficult to treat as the strain does not respond to the antibiotics typically used to treat the bacteria. While it has been found across England, cases are concentrated in London (45), the North West (21) and South East (12). Shigella is an infectious gut infection that can cause symptoms like diarrhoea (sometimes mixed with blood), stomach cramps and fever, which are commonly mistaken for food poisoning.

A new, independent search engine has launched called Vitaminology which enables the search, discovery and comparison of vitamins and supplements to empower consumers to make more informed choices and find the right products for their personal health goals and requirements. The company has set out to reduce confusion in this market through choice and high-quality information as well as access to one-to-one consultations with accredited nutritional therapists. By offering the complete package of advice, resources and products Vitaminology helps people to lead healthier lives. Mike Murphy, who is chief nutritionist for Vitaminology, comments, "This innovative platform has a powerful comparison and filtering feature that helps to simplify the choices available for consumers so they can make better self-care decisions. This is supported by access to video consultations with nutritional therapists as well as a comprehensive library of ingredient profiles, articles clustered around health conditions and unique recipes to support wellness."

As we begin the near year, experts are still working hard to learn more about COVID-19 to learn how to fight it. We caught up with a lead researcher in Taiwan about new information he has discovered about the origin of the novel virus. There's an unusual pattern found during the COVID investigation process by Atossa Therapeutics called genetic cluster. Let's found out what Dr. Steven Quay and Fox News has to say about it.